DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Bulletin > Acta Medica Nagasakiensia > Volume 61, No. 4 >

Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan

File Description SizeFormat
ActMed61_167.pdf1.01 MBAdobe PDFView/Open

Title: Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan
Authors: Kohno, Shigeru / Izumikawa, Koichi / Ogawa, Kenji / Kurashima, Atsuyuki / Okimoto, Niro / Suzuki, Katsuhiro / Kakeya, Hiroshi / Niki, Yoshihito / Ichihara, Kiyoshi / Miyazaki, Yoshitsugu
Issue Date: Mar-2018
Publisher: Nagasaki University School of Medicine / 長崎大学医学部
Citation: Acta medica Nagasakiensia, 61(4), pp.167-176; 2018
Abstract: Chronic pulmonary aspergillosis (CPA) is slowly progressive inflammatory pulmonary syndrome due to infection of Aspergillus spp. We conducted a randomized, multicenter, open-label trial comparing intravenous liposomal amphotericin B (L-AMB) of 2.5-5.0 mg/kg once daily with intravenous voriconazole (VRCZ) of 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily. Treatment effectiveness was defined by clinical, and radiological improvement at both 2 weeks after the initial administration and at the end of therapy. The total of 166 patients were recruited and 83 patients for each drug group were assigned. Total of 51 and 59 cases of L-AMB and VRCZ, respectively were assessed as per-protocol populations. The difference in efficacy rates between L-AMB and VRCZ was not significant, either after 2 weeks [49.0% vs. 59.3%; the absolute difference, 10.3% with a 95% confidence interval (CI), -8.4 to 29.00, P=0.279] or at the end of therapy (52.9% vs. 67.8%; the absolute difference, 14.9% with a 95% CI, -3.4 to 33.2, P=0.111). In the safety evaluation, no statistical difference of occurrence rates in both LAMB and VRCZ group (54.2% vs. 59.0%, P=0.531). L-AMB was as effective as VRCZ with no significant difference of adverse effects in the treatment of CPA. (UMIN Clinical Trials Registry number, UMIN000002236.)
Keywords: chronic pulmonary aspergillosis / liposomal amphotericin B / voriconazole
URI: http://hdl.handle.net/10069/38193
ISSN: 00016055
Relational Links: http://hdl.handle.net/10069/38673
Type: Departmental Bulletin Paper
Text Version: publisher
Appears in Collections:Volume 61, No. 4

Citable URI : http://hdl.handle.net/10069/38193

All items in NAOSITE are protected by copyright, with all rights reserved.


Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace